Print This Page

Cannabis Provides Strong Pain Relief

Cannabis (Cannabis sativa L.) has been the topic of a lot of discussion in the U.S., not just in recent decades but for more than a century. It’s been one of the most controversial plants worldwide, arguably more than poppies and peyote.

What’s hard to argue with, however, are the clinical findings that the pain-relieving effects of the cannabis plant are 30 times more potent than aspirin for decreasing inflammation, according to scientists at the University of Guelph in Ontario, Canada, a country where cannabis use became legal as of October 17, 2018.1

Tariq Akhtar and Steven Rothstein, professors in the molecular and cellular biology department at McGill University Health Center, worked with five colleagues on the study, observing that besides the psychoactive aspects of tetrahydrocannabinol (THC) and the pharmacological features of cannabinoids such as cannabidiol (CBD) derived from C. sativa varieties, there’s potential for numerous medicinal uses.

One of the points made by the study, published by the journal Phytochemistry,2 is the plant’s “medicinal versatility,” and its focus on two specific molecules, cannflavin A and cannflavin B. Interestingly, the research notes that cannflavins A and B first came to light in 1985 when the benefits were compared to acetylsalicylic acid, the product sold as “aspirin.”

Because research on cannabis has been regulated diligently in Canada, not to mention the U.S., decades of stymied opportunities for discovery were lost due to the ban on its use. Once the ban was lifted, however, Akhtar and Rothstein proceeded, further armed with advanced genomic research.

What’s next: Engineering the molecules

The team’s stated objective was to “better understand how these molecules are made,” Akhtar noted. “There are many sequenced genomes that are publicly available, including the genome of Cannabis sativa, which can be mined for information. If you know what you’re looking for, one can bring genes to life, so to speak, and piece together how molecules like cannflavins A and B are assembled.”3

To identify the biosynthesis producing the two “medicinally relevant cannabis compounds,” the scientists explained:

“Evidence is presented for an O-methyltransferase (CsOMT21) encoded within the C. sativagenome that specifically converts the widespread plant flavone known as luteolin to chrysoeriol, both of which accumulate in C. sativa. These results therefore imply the following reaction sequence for cannflavins A and B biosynthesis: luteolin ► chrysoeriol ► cannflavin A and cannflavin B.”4

Separate studies establish that flavones serve as antioxidant,5 neuroprotective6and anticancer7 resources when ingested. It’s worth noting that while other plants have been examined to determine similar biosynthetic pathways, oddly, cannabis had not until recently.8

Now, however, the team is working with Canadian company Anahit International Corp., which holds a licensed patent from the university, to develop a “biological system to create these molecules, which would give us the opportunity to engineer large quantities,”9 Rothstein said.

Anahit executives said the company plans to work further with the researchers to “develop effective and safe anti-inflammatory medicines from cannabis phytochemicals that would provide an alternative to non-steroidal anti-inflammatory drugs,” according to chief operating officer Darren Carrigan, who explained what will come next: “Anahit will commercialize the application of cannflavin A and B to be accessible to consumers through a variety of medical and athletic products such as creams, pills, sports drinks, transdermal patches and other innovative options.”10

The reason that’s important, is that currently in the U.S., people looking for pain relief often turn to opioids, popular because they can effectively block the pain receptors in your brain, but there are two major downsides: numerous side effects and a very real likelihood of addiction.

The continuing case for cannabis Cannflavins A and B were also discussed in a collaborative study in 2014, which found the foundational source of their potent action came from “two pro-inflammatory mediators, prostaglandin E2 and the leukotrienes.”11 The seeds were found to lack the usual phenolics found in hemp leaves and flower heads, and sprouting them produced cannflavins A and B, they did not trigger cannabinoids.

Further: “Hemp seeds are of great nutritional value, containing all essential amino acids and fatty acids in sufficient amount and ratio to meet the dietary human demand. Hemp seeds do not contain cannabinoids, and because of their high contents of ω fatty acids, are enjoying a growing popularity as a super-food to beneficially affect chronic inflammation.”12

In 2018, another Canadian study produced by McGill University Health Center and led by Gabriella Gobbi, professor of psychiatry and researcher in the Brain Repair and Integrative Neuroscience (BRaIN) Program at McGill, reported that CBD, being free from side effects, is a safe alternative to prescription drugs for pain relief, without the “high” associated with THC.
The team was able to demonstrate that CBD doesn’t work on CB1 cannabinoid receptors in the way THC does, but rather through the specific receptor mechanisms concerned with anxiety, called serotonin 5-HT1A, as well as pain, known as vanilloid TRPV1.

The scientists also extrapolated the precise dosage of CBD for analgesic and anxiety relief, as well as for chronic back, sciatica, diabetic, cancer and other types of pain. Postdoctoral fellow at McGill University and the study’s first author, Danilo De Gregorio, added, “We found in animal models of chronic pain that low doses of CBD administered for seven days alleviate both pain and anxiety, two symptoms often associated in neuropathic or chronic pain.”13

Gobbi called the research a “new advancement for an evidence-based application of cannabis in medicine”14 — pain relief without the euphoria, and more importantly, without the risk of addiction. Notably, the FDA approved CBD oil 15 in a purified form known as Epidiolex by prescription for two types of epilepsy.

Sources: OCA, 8/5/19,

1 Global News October 16, 2018
2, 4 Phytochemistry August 2019 Volume 164 pages 162-171
3, 9, 10 Medical Xpress July 24, 2019
5 J Nat Prod. 2000; 63, 1035-1042
6 Brain Research Bulletin July 23, 2015
7 Cancer Letters August 9, 2017 413,11-22
8 Frontiers in Plant Science February 4, 2016
11, 12 PharmaNutrition May 12, 2014 53-60
13 McGill University Health Centre October 24, 2018
14 EurekAlert October 24, 2018
15 FDA June 25, 2018


Back to Organic Records Search